Gilead Sciences (GILD) could be a great long-term investment
What’s up with Gilead Sciences?
Gilead Sciences (GILD) opened at $77.76, which means the stock is down 0.32% from yesterday’s closing price of 77.61. Today, the company has a high of $78.44 and a low of $76.87. The company has a market cap of $97.20 billion with a 52-week high of $85.97 and a 52-week low of $60.89.
What about the future for Gilead Sciences?
The high forecast for Gilead Sciences is 97.00 while the low is 58.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Gilead Sciences has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information GILD seems to be a safe buy.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.